Meeting
2014 ASCO Annual Meeting
Inotuzumab ozogamicin (IO) in combination with low-intensity chemotherapy as front-line therapy for older patients (pts) and as salvage therapy for adult with R/R acute lymphoblastic leukemia (ALL).
Authors
Elias Jabbour
The University of Texas MD Anderson Cancer Center, Houston, TX
Elias Jabbour , Susan Mary O'Brien , Nitin Jain , Deborah A. Thomas , Guillermo Garcia-Manero , Farhad Ravandi , Gautam Borthakur , Sergernne York , Rebecca Garris , Jorge E. Cortes , Hagop M. Kantarjian
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Leukemia, Myelodysplasia, and Transplantation
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Leukemia
Clinical Trial Registration Number
NCT01371630
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 7019)
DOI
10.1200/jco.2014.32.15_suppl.7019
Abstract #
7019
Poster Bd #
11
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Updated results of a phase I/II study of inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-hyper-CVD) as frontline therapy for older patients with acute lymphoblastic leukemia.
First Author: Nicholas James Short
Poster
2017 ASCO Annual Meeting
Inotuzumab ozogamicin (IO) combined with mini-hyper-CVD as salvage therapy for patients (pts) with R/R acute lymphoblastic leukemia (ALL).
First Author: Rita Assi
Poster
2013 ASCO Quality Care Symposium
Improving the care of acute lymphocytic leukemia (ALL) at a large county hospital.
First Author: Meghan Sri Karuturi
Poster
2022 ASCO Annual Meeting
A phase II study of hyper-CVAD with sequential blinatumomab (Blina), with or without inotuzumab ozogamicin (INO), in adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL).
First Author: Nicholas James Short